Abstract Library

#4180 Non-functional alpha-cell hyperplasia with glucagonoma: A case report

Introduction: Alpha-cell hyperplasia(ACH) is a rare pancreatic endocrine condition. Clinically, 3 types have been described: functional ACH (nonglucagonoma hyperglucagonemic glucagonoma syndrome), reactive ACH (secondary to defective glucagon signalling) and non-functional ACH. Few cases of ACH and non-functional pancreatic neuroendocrine tumors (pNET) have been reported and its aetiology remains poorly understood.

Conference:

Presenting Author: Santos A

Authors: Cidade Rodrigues C, Santos A, Calheiros R, Santos S, Matos C,

Keywords: alpha-cell hyperplasia, diabetes, glucagon, pancreas, neuroendocrine tumor,

#4036 Metformin inhibits small intestinal neuroendocrine tumor proliferation in vivo

Introduction: Small intestinal neuroendocrine tumors (SI-NETs) are rare and slow-growing, with most patients being diagnosed at a late stage with distant metastases. Metformin has been hypothesized as a potential anti-tumor agent by several studies in the past few years. This has been further confirmed by experimental studies in which metformin has inhibited cancer cell growth in different cancers, and we recently demonstrated that metformin treatment repressed the cell viability of SI-NET cells and inhibited the proliferation of cell spheroids.

Conference:

Presenting Author:

Authors: Axling F, Hellman P, Norlén O, Stålberg P, Barazeghi E,

Keywords: neuroendocrine neoplasm, SI-NET, in vivo model, metformin, RNA-seq, miRNA-seq, xenograft,

#3630 Metformin suppresses small intestinal neuroendocrine tumor growth in vivo

Introduction: Small intestinal neuroendocrine tumors (SI-NETs) are rare and slow growing, but most patients are diagnosed at a late stage with distance metastases. In the past few years, several studies have reported the anti-tumor activity of metformin in different cancers, and recently we showed that metformin treatment repressed cell viability of SI-NET cells and inhibited the growth of GOT1 spheroids.

Conference:

Presenting Author:

Authors: Barazeghi E, Axling F, Hellman P, Norlén O, Stålberg P,

Keywords: neuroendocrine tumor, metformin, SI-NET xenograft,

#3543 Safety of Lanreotide Autogel (LAN) 120 mg plus Metformin (MET) in patients with advanced, well-differentiated (WD) gastro-intestinal (GI) or lung neuroendocrine tumors (NETs) - A pilot, open-label, prospective study: The MetNET-2 Trial (NCT02823691)

Introduction: Preclinical and clinical evidence supports a potential role for MET as an antineoplastic agent in WD NETs.

Conference:

Presenting Author: Pusceddu S

Authors: Pusceddu S, Prinzi N, Corti F, Beninato T, Milione M,

Keywords: neuroendocrine tumor, metformin, somatostatin analogues,

#3497 Activity and safety of metformin (MET), Everolimus (EVE) and Octreotide (OCT) in patients (pts) with advanced, well-differentiated (WD) pancreatic neuroendocrine tumors (pNETs). The prospective phase II MetNET-1 trial (NCT02294006). Interim analysis

Introduction: Preclinical and clinical evidences support a role for metformin as an antineoplastic agent in WD pNETs.

Conference:

Presenting Author: Pusceddu S

Authors: Pusceddu S, Prinzi N, Corti F, Beninato T, Milione M,

Keywords: pancreatic NET, metformin, somatostatin analogues, everolimus,